To assess high-dose carboplatin chemotherapy with or without paclitaxel with filgrastim mobilized peripheral blood progenitor cell (PBPC) support in a phase I/II study, a total of 21 patients with mostly chemonaive disease received four cycles of high-dose chemotherapy. Cycle 1 (cyclophosphamide, 6 g/m The prognosis for patients with advanced ovarian cancer remains poor in spite of the fact that combination chemotherapy, including platinum compounds, yields response rates between 60% and 80%.
The prognosis for patients with advanced ovarian cancer remains poor in spite of the fact that combination chemotherapy, including platinum compounds, yields response rates between 60% and 80%. 1, 2 Long-term disease control occurs in 20% to 30% of women with stage III disease, in less than 10% of women with incompletely resected stage III disease, and in less than 5% of women with stage IV disease. 3, 4 These disappointing results are presumably due to the resistance of the disease to standard chemotherapy. 5 A retrospective analysis performed by Levin and Hryniuk 6 demonstrated a significant correlation between increased dose-intensity of cisplatin, response rate, and overall survival. Several randomized trials have addressed the role of dose intensity of chemotherapy in ovarian cancer. Maximum dose intensification in these studies was twofold. The results were inconclusive and the merit of dose intensification remains unproven. 7, 8 According to in vitro studies, a minimum four-fold increase in dose intensity is necessary to overcome resistance to chemotherapy. [9] [10] [11] Single high-dose chemotherapy followed by stem cell rescue results in a four-fold or higher dose intensity compared to standard chemotherapy. This therapy yields remission rates between 50% and 80%, even in relapsed patients. [12] [13] [14] [15] [16] [17] A recent study reported long-term results in chemosensitive stage III and stage IV ovarian cancer patients with 5-year overall survival and diseasefree survival rates of 71% and 27%, respectively. 18 These results were promising, but the outcome of ongoing randomized trials in the US (NCI and GOG high-priority study) and in France must be awaited to determine the success of single high-dose chemotherapy. 19 It is known from both cell culture and clinical experience that drug resistance may develop early during chemotherapy in ovarian cancer patients. 5, 9 It may be necessary, therefore, to treat patients with high doses of the most active chemotherapy agents from the onset, and not only in consolidation therapy. 20, 21 Taking into account the theoretical considerations of tumor-cell biology developed by Goldie and Coldman 22 and tumor-cell kinetics stated in the Norton-Simon hypothesis, 23 the two common features of successful treatment programs for chemotherapy-treatable 2 ) seven patients. Cohort 3 (Carboplatin 1600 mg/m 2 ϩ paclitaxel) eight patients. All PBPC rescues were followed by filgrastim 5 g/kg/day starting on day ϩ1 in patients 6-21 and starting on day ϩ6 in patients 1-5. Treatment intervals 3-4 weeks resulting in a treatment duration between 12 and 16 weeks for four cycles. solid tumors are: (1) the availability of a regimen capable of producing complete remissions; and (2) the feasibility of delivering a certain number of cycles of this regimen in full doses early in the course of the disease.
With the administration of granulocyte colony-stimulating factor (G-CSF, filgrastim) shortly after chemotherapy, large numbers of peripheral blood progenitor cells (PBPCs) can be collected allowing for repeated cycles of high-dose chemotherapy. 24, 25 Leukocyte and thrombocyte nadirs last about 1 week. The total therapy-related mortality rate is approximately 2% to 5%. [26] [27] [28] The maximum tolerated dose (MTD) of a single high-dose cycle of carboplatin (1800 to 2000 mg/m 2 ) followed by autologous stem cell rescue was determined in solid tumors. 29, 30 Ototoxicity, hepatotoxicity, and renal toxicity were found to be dose-limiting for carboplatin. A single high dose of carboplatin at 1600 mg/m 2 can be safely administered in combination with other chemotherapy agents. 29, 31, 32 Repeated high-dose carboplatin chemotherapy within the range of 1000 to 1200 mg/m 2 has been tested recently in several types of solid tumors. 25, 26, 28 We performed a phase I/II study evaluating the feasibility and toxicity of carboplatin dose escalation. In addition to the primary objective of evaluating the maximum tolerated dose of sequential carboplatin with or without paclitaxel, secondary objectives included evaluating response rates, progression-free survival, and overall survival.
Patients and methods

Debulking surgery
All patients were FIGO stage III and IV. Stage III patients had either tumor residue Ͼ2 cm in diameter or prior extensive infiltration of the intestine or upper abdomen. Beside standard debulking surgery for ovarian cancer in 11 patients extensive surgery was performed including parietal and visceral deperitonisation, splenectomy, retroperitoneal lymph node dissection, and resection of parts of the small and large bowel, mainly the colon sigmoideum and the iliocoecal region. Five patients were determined by the referring gynecologist to be inoperable following exploratory laparotomy and did not undergo debulking surgery.
Treatment plan and dose escalation
Chemotherapy was started 3 to 4 weeks after debulking surgery. The first cycle of therapy was supported by PBPCs collected after a minimum of 4 days of filgrastim (5 or 10 g/kg/day s.c.) priming. The chemotherapy cycles administered and the PBPC collections performed are specified in Table 1 .
Dose escalation of carboplatin started at 1600 mg/m 2 with planned doses increasing to 1800 and 2000 mg/m 2 . Carboplatin dose was increased if no dose-limiting toxicities (DLTs) were reported in a minimum of four patients. After 13 patients (cohort 1 and 2) the MTD of carboplatin was reached and further intensification of therapy was achieved in the next eight patients with the addition of paclitaxel (175 mg/m 2 ) given in all chemotherapy cycles. Paclitaxel was administered before carboplatin in all cycles.
Assessment of toxicity and response
Ototoxicity was assessed using NCI criteria after each carboplatin cycle. Audiometry was performed at the end of sequential high-dose chemotherapy and during follow-up. All other toxicities and the responses were assessed using the WHO criteria. Progression was assessed clinically as needed with the aid of imaging techniques, or retrospectively, the first time that a tumor marker, Ca-125, increased. Progression-free and overall survival were calculated from the start of high-dose chemotherapy. Routine second-look surgery was not required in this study.
PBPC collection
In steady-state leukaphereses before the first treatment cycle at least 1 ϫ 10 6 CD34 ϩ cells/kg body weight should be collected. The leukapheresis product following highdose cyclophosphamide ϩ/Ϫ paclitaxel was divided into at least three separate portions with a minimal CD34 ϩ cell content of 2 ϫ 10 6 /kg body weight each.
Calculation of dose intensity
Weekly dose intensity of chemotherapy was calculated as a function of the actual dose of drug received divided by the number of weeks elapsed between the initial dose of carboplatin and 3 weeks after the last cycle of chemotherapy. 33 
Statistical analysis
The unpaired Student's t-test and Fisher's exact test were used to compare the duration of leukocytopenia, numbers of CD34 ϩ cells, and colony-forming units in PBPC harvest products from each cohort. Progression-free and overall survival were calculated using the Kaplan-Meier analysis.
The study was approved by the local Ethics Committee and written informed consent was obtained from all patients before entry into the study.
Results
A total of 21 patients with advanced ovarian cancer and performance status of maximal ECOG 2 were enrolled in this study. Patients were treated in three cohorts: cohort 1 (carboplatin 1600 mg/m 2 ) 6 patients; cohort 2 (carboplatin 1800 mg/m 2 ) seven patients and cohort 3 (carboplatin 1600 mg/m 2 ϩ paclitaxel 175 mg/m 2 for all cycles) eight patients. Patients received a total of 82 repetitive cycles of high-dose chemotherapy. All but two patients completed the entire treatment plan. Due to increasing discomfort from ototoxicity one patient in cohort 1 omitted cycle 3 and proceeded directly to the last consolidation cycle. One patient in cohort 3 opted not to proceed to the fourth cycle following recovery of gram-negative sepsis and tubular acidosis during cycle 3. Fourteen patients were previously untreated, seven patients were pretreated. Five pretreated patients experienced relapse more than 6 months (9 months up to 4 years) after their prior chemotherapy. Three of these patients had a prior good partial remission, two a complete remission. Two patients presented with platin-resistant cancer progressing within 3 months after their last chemotherapy. All pretreated patients had previously received a minimum of five cycles of cisplatin or carboplatin combined with cyclophosphamide in conventional doses. Patient characteristics and their risk profiles are listed in Tables 2 and 3 . 
PBPC collection
A median number of 2.02 ϫ 10 6 CD34 ϩ cells/kg were collected before chemotherapy in steady state. Following the first cycle, a median number of 25.5 ϫ 10 6 CD34 ϩ cells/kg were collected (Table 4 ). The addition of paclitaxel in cohort 3 not only did not impair, but further increased the number of CD34 ϩ cells and CFUs in PBPC products. Overall, sufficient PBPCs were collected after the first cycle of cyclophosphamide (ϩ/Ϫ paclitaxel) to support all subsequent chemotherapy cycles. Only one patient who was pretreated with six cycles of cyclophosphamide and cisplatin required an additional bone marrow harvest.
Hematological toxicity
The duration of leukopenia (WBC Ͻ1.0 ϫ 10 9 /l) and thrombocytopenia (Ͻ20 ϫ 10 9 /l) was relatively short throughout all cycles and dose levels as indicated in Table 5 .
Red blood cell and platelet transfusion requirements were equally distributed over all cycles (Table 6 ). Patients received prophylactic platelet and red cell transfusion if platelet count fell below 15 ϫ 10 9 /l and hemoglobin levels were Ͻ80 g/l. Table 6 Number of red blood cell and platelet transfusions per patient The first five patients treated in this study received filgrastim starting on day ϩ6 after PBPC reinfusion. The next 16 patients received filgrastim starting on day ϩ1. Those patients who received filgrastim earlier had a median leukopenic phase that was approximately 2 to 3 days shorter in each of cycles 1 to 4 compared with patients who started filgrastim on day ϩ6. The shortened duration of leukocytopenia was caused by a rapid increase of leukocytes after administration of filgrastim on days ϩ1 and ϩ2 . A short nadir followed until a rapid regeneration of neutrophils did happen. The numbers of PBPCs, CD34 ϩ cells, or CFUs transfused in these two groups were comparable (data not shown).
Ototoxicity
Ototoxicity was found to be dose-limiting and occurred overall in 86% of patients following three repetitive cycles of high-dose carboplatin (NCI grade 1, 2, 3 in 29%, 52% and 5%, respectively). Ototoxicity grade 3 occurred at carboplatin doses of 1800 mg/m 2 (cohort 2) with a calculated maximum area under the plasma concentration-time curve (AUC) of 29 mg/ml ϫ min according to the formula of Calvert. 34 One additional patient in cohort 2, who experienced a severe grade 2 ototoxicity but did not necessarily require a hearing aid, was also judged as dose-limiting ototoxicity. This patient had a calculated maximum AUC of 26 mg/ml ϫ min. Administration of three sequential cycles of carboplatin at 1600 mg/m 2 , therefore, was determined to be the MTD in this treatment regimen. A clear relationship between ototoxicity and AUC (median) of carboplatin was observed after correlating ototoxicity to the calculated maximum AUC in 19 patients for whom EDTA clearance was available ( affected higher frequencies of between 4 and 8 kHz ( Table  8 ). The median hearing loss detected by audiometry averaged 40 to 60 dB. Three to 4 months following the last chemotherapy cycle, tolerable hearing impairment (рgrade 2) did not compromise patients' normal lives. Tinnitus was reversible in six of 14 patients (43%) and was well tolerated in the other eight patients who were followed for more than 1 year after treatment. Hearing loss of higher frequencies detected by audiometry did not change over time and continued after a maximum follow-up of 38 months. In some patients, conversational hearing was impaired, particularly with regard to female voices or several people speaking at once. At times, very high frequency sounds, such as birds, were experienced as troublesome.
Other non-hematological toxicities
WHO grade 3 and 4 diarrhea was observed in approximately 30% of patients during the first three cycles and in 60% of patients during the fourth cycle. This observation was similar throughout all three cohorts. In all three treatment cohorts only one patient developed WHO grade 2 neurotoxicity. Interestingly, in the eight patients who received paclitaxel for all treatment cycles no grade 2 neurotoxicity was observed. Nephrotoxicity was seen in only one patient in cohort 3 who developed transient tubular acidosis after two cycles of carboplatin at 1600 mg/m Table 8 Hearing loss on audiometry after sequential high-dose carboplatin 
Response to therapy
All 21 patients were evaluable for efficacy. All patients had either residual tumor measurable with imaging techniques, malignant effusion or elevated CA-125 at start of chemotherapy. The overall complete (11 of 21) and partial (10 of 21) response rate was 100%. Second-look surgery or interventional surgery was performed in eight patients. All six patients with partial remission who underwent secondlook surgery were found to have viable tumor cells ( Table  2 ). The median follow-up of women surviving at last contact was 22.5 months (range 15 to 38 months). Twelve patients were alive between 15 and 38 months and eight patients were progression-free between 15 and 36 months after chemotherapy. None of the four patients with optimal debulking surgery and carboplatin-sensitive disease relapsed while 13 out of 17 patients relapsed after suboptimal debulking or platin resistance. All five patients with elevated Ca-125 before the consolidation cycle 4 have relapsed between 7 and 30 months ( Table 2) . Median progression-free survival was 25 months median overall survival was 36.5 months for all patients. Previously untreated patients had a slightly better outcome (Figures 1 and 2 ).
Discussion
Four cycles of high-dose chemotherapy supported by PBPC transplantation are feasible with acceptable toxicity a few weeks after extensive surgery in patients with advanced /week can be achieved. Ototoxicity was dose-limiting in this study of sequential dose escalation of carboplatin. Carboplatin 1600 mg/m 2 was shown to be the MTD for sequential high dose chemotherapy with a treatment interval of 3 to 4 weeks in patients with prior normal renal function. Ototoxicity following single high-dose carboplatin has been well documented in studies with dose ranges from 1200 to 2400 mg/m 2 . 14, 29, 30 In a study reporting on accelerated delivery of multiple courses of high-dose carboplatin with a treatment interval of 2 weeks 1000 mg/m 2 proved to be the MTD due to ototoxicity. 35 In our study tinnitus and hearing impairment of normal speech range improved over time while hearing loss at higher frequencies (Ͼ3 kHz) of 40 to 60 dB was unchanged up to a maximum follow-up period of 38 months. Our results are in parallel with a study showing that a dose-intensity of carboplatin Ͼ300 mg/m 2 /week may result in hearing loss, with higher frequencies affected first. 36 Neurotoxicity was not a problem in our study even after the addition of 175 mg/m 2 of paclitaxel to all four cycles in cohort 3. Notably, the addition of paclitaxel to the regimen did not increase any toxicity. This observation was in contrast to a study performed in patients with different solid tumors with 250 mg/m 2 of paclitaxel plus escalating doses of carboplatin at AUC 8 to 20 mg/ml ϫ min infused over 1 h. 37 In this study, neurotoxicity was dose limiting with two grade 3 foot drops reported with AUCs of 18 and 20, a dose that was lower than that used in most of our patients. This may be attributed to the higher dose of paclitaxel than we used and probably related to the short 1-h carboplatin infusion. Diarrhea was another important non-hematological toxicity. This transient well-known side-effect of high-dose carboplatin is correctable in part by oral opium tincture or octreotide at 0.3 to 1.5 mg/day administered i.v. as a continuous infusion, or s.c. every 8 h. 14, 25, 30, 38 Mucositis was seen exclusively after cycle 4 which was clearly attributed to the combination of high-dose etoposide and melphalan. Hematological toxicity lasted only a few days and did not increase over cycles due to the transplantation of sufficient numbers of PBPCs after each cycle. No treatment-related mortality was observed. The very short duration of leukocytopenia in our study with a median of 4 days during cycles 2 and 3, was related to the early start (day ϩ1) of filgrastim following reinfusion of PBPCs in comparison to a later start (day ϩ6) where leukocytopenia lasted 2 to 3 days longer. As shown in the allogeneic transplantation setting, this shortening of leukocytopenia is clearly related to the stimulation of leukocytes from the patient's bone marrow and not from the transplanted PBPCs. 39 There is an ongoing debate on how to calculate the carboplatin dose. It is clear that the effective carboplatin dose per patient can be better calculated according to the Calvert formula on the basis of creatinine or EDTA clearance. 34, 40 Therefore future studies with high-dose carboplatin should be probably performed on the basis of the projected AUC. The maximum tolerated AUC of carboplatin calculated retrospectively in our study was approximately 22 mg/ml ϫ min.
The high response rate and the actuarial median progression-free survival of 25 months and a median overall survival of 36.5 months for patients with advanced, mostly suboptimally debulked cancer and more than 50% presenting with FIGO stage IV is promising. The median progression-free survival in our study is about 7 to 11 months longer than what would be expected with optimal standard chemotherapy. It clearly calls for confirmation with a phase III study where sequential high-dose chemotherapy must be compared with the best conventional chemotherapy as published by the GOG and the EuropeanCanadian Ovarian Cancer Intergroup. 41, 42 A recent overview of 100 autologous transplantations in relapsed or platin-resistant ovarian cancer patients in the US and a long-term follow-up study of 53 ovarian cancer patients in France, who were primarily transplanted after first-line standard chemotherapy, has shown that patients after optimal debulking surgery and with platin-sensitive cancer are the group benefiting the most from high-dose chemotherapy. 18, 43 This also seems to be true in our study for patients receiving sequential high-dose chemotherapy. None of the patients after optimal debulking surgery and platin-sensitive disease relapsed. Consequently, those patients are the best candidates for sequential high-dose chemotherapy programs. In these patients, upfront highdose chemotherapy may offer the greatest probability of avoiding the development of chemotherapy resistance. 21, 23 Recently, Gianni et al 44 published a randomized study of this approach in patients with aggressive B cell lymphoma offering the first evidence that the concept of sequential high-dose chemotherapy may provide clinical benefit. On the basis of the experiences of Fennelly et al, 26 Viens et al, 16 and the study presented here, the European Blood and Marrow Transplantation Group (EBMT) has started a prospective randomized study in optimally debulked (Ͻ2 cm) patients with advanced ovarian cancer FIGO stage III and IV. This study will compare sequential high-dose carboplatin chemotherapy, AUC 20 plus paclitaxel (200 mg/m 2 ) and the addition of melphalan (140 mg/m 2 ) for the last cycle supported by PBPC transplantation after each cycle, with a conventional combination chemotherapy including the most active agents cis-or carboplatin and paclitaxel.
